Antigenics Inc.  (AGEN) Trade Now »     Rate AGEN  -  Discuss AGEN  -  Add to Watch List        

Shares of Antigenics (AGEN) have traded with increased volatility during Monday's and early Tuesday's trading sessions which could be an indicator that news is pending.

The company's Russian launch of its kidney cancer vaccine Oncophage is set to take place in the fourth quarter of this year, according to previous announcements by the company, and news of Russian government reimbursement should hit the wires before that time.

Adam Feuerstein's video message of why Antigenics (AGEN) stinks is another fine example of why the small investor should not trust the big boys to look out for them. Anyone paying a subscription to the sham of an organization known as "The Street.com", shame on you. They have an agenda, and it has nothing to do with making you money.

The Antigenics (AGEN) updates may be getting quite burdensome for some, but with all the recent volatility of the stock and the potential of the company's products, Oncophage and QS-21, it's worth keeping a steady eye on the stock that was labeled a potential 10-bagger by Jeff P Opdyke in Sunday's Wall Street Journal.

The article was titled "Five Stock Picks for Your Recovering Portfolio" and the Antigenics portion was actually authored by Dick McCormick of Elite Growth & Income Fund.